Immunotherapies developer Scancell has launched a research programme focused on the development of a DNA vaccine candidate to protect from Covid-19.

The project will involve researchers from the University of Nottingham, Centre for Research on Global Virus Infections, the Biodiscovery Institute and Nottingham Trent University.

DNA vaccines by Scancell target dendritic cells to induce high avidity T-cells that identify and destroy diseased cells.

The company’s lead candidate is an ImmunoBody cancer vaccine, SCIB1, which demonstrated safety and five-year survival in malignant melanoma patients in Phase I/II clinical trials.

Scancell intends to develop a safe, cost-effective and scalable vaccine that could trigger durable T-cell responses as well as virus neutralising antibodies (VNAbs) against Covid-19 infection.

The T-cell plus antibody approach could deliver potent and long-lasting responses. The vaccine will be designed to act on the SARS-CoV-2 nucleocapsid (N) protein, as well as the main receptor-binding domain of the spike (S) protein.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As the N protein is present in many coronaviruses, the vaccine could generate protection against SARS-CoV-2 as well as any coronavirus strains arising in the future.

Scancell chief scientific officer Lindy Durrant said: “As the Covid-19 pandemic has unfolded, Scancell has been evaluating how it can best contribute its expertise and resources to help in the global response.

“Vaccines are the long-term solution and we believe our combined high avidity T-cell and neutralising antibody approach has the potential to produce a second-generation vaccine that will generate an effective and durable immune response to Covid-19.”

Initial research is ongoing; the company expects to launch a Phase I trial in the first quarter of next year, contingent on funding.

In addition, Scancell is looking for development partners and additional funding to accelerate the development of the vaccine candidate.